Literature DB >> 21325417

Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.

Moira A McMahon1, Teresa L Parsons, Lin Shen, Janet D Siliciano, Robert F Siliciano.   

Abstract

Acyclovir, a nucleoside analog, is thought to be specific for the human herpesviruses because it requires a virally encoded enzyme to phosphorylate it to acyclovir monophosphate. Recently, acyclovir triphosphate was shown to be a direct inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. Here, we showed that acyclovir is an inhibitor of HIV-1 replication in CD4(+) T cells from cord blood that have undetectable levels of the eight human herpesviruses. Additionally, acyclovir phosphates were detected by reverse-phase-high performance liquid chromatography (RP-HPLC) and quantified in a primer extension assay from cord blood. The data support acyclovir as an inhibitor of HIV-1 replication in herpesvirus-negative cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325417      PMCID: PMC3126274          DOI: 10.1128/JVI.02423-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1.

Authors:  J D Mosca; D P Bednarik; N B Raj; C A Rosen; J G Sodroski; W A Haseltine; G S Hayward; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Prevalence of antibody to human herpesvirus 7 by age.

Authors:  D A Clark; M L Freeland; L K Mackie; R F Jarrett; D E Onions
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

3.  Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate.

Authors:  J E Reardon; T Spector
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

4.  Human herpesvirus-6 infection in children. A prospective study of complications and reactivation.

Authors:  C B Hall; C E Long; K C Schnabel; M T Caserta; K M McIntyre; M A Costanzo; A Knott; S Dewhurst; R A Insel; L G Epstein
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

5.  Activation of human immunodeficiency virus by herpes simplex virus.

Authors:  M P Golden; S Kim; S M Hammer; E A Ladd; P A Schaffer; N DeLuca; M A Albrecht
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

6.  Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.

Authors:  S Weller; M R Blum; M Doucette; T Burnette; D M Cederberg; P de Miranda; M L Smiley
Journal:  Clin Pharmacol Ther       Date:  1993-12       Impact factor: 6.875

7.  Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells.

Authors:  D F Smee; R Boehme; M Chernow; B P Binko; T R Matthews
Journal:  Biochem Pharmacol       Date:  1985-04-01       Impact factor: 5.858

8.  Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids.

Authors:  A K Datta; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes.

Authors:  D M Margolis; A B Rabson; S E Straus; J M Ostrove
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

10.  Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population.

Authors:  J A Levy; F Ferro; D Greenspan; E T Lennette
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

View more
  9 in total

1.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors.

Authors:  Richard A Voit; Moira A McMahon; Sara L Sawyer; Matthew H Porteus
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

3.  Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.

Authors:  Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis
Journal:  Clin Infect Dis       Date:  2015-03-03       Impact factor: 9.079

4.  High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Authors:  Tara Perti; Misty Saracino; Jared M Baeten; Christine Johnston; Kurt Diem; Negusse Ocbamichael; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

5.  High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Authors:  Kenneth Mugwanya; Jared M Baeten; Nelly R Mugo; Elizabeth Irungu; Kenneth Ngure; Connie Celum
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

Review 6.  Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Authors:  Christine Johnston; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 7.  The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature.

Authors:  Helen M Chun; Robert J Carpenter; Grace E Macalino; Nancy F Crum-Cianflone
Journal:  J Sex Transm Dis       Date:  2013-06-24

8.  The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.

Authors:  Stephanie C Gordts; Geoffrey Férir; Thomas D'huys; Mariya I Petrova; Sarah Lebeer; Robert Snoeck; Graciela Andrei; Dominique Schols
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

9.  SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.

Authors:  Paula Ordonez; Simone Kunzelmann; Harriet C T Groom; Melvyn W Yap; Simon Weising; Chris Meier; Kate N Bishop; Ian A Taylor; Jonathan P Stoye
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.